Novartis fights back in COPD with publication of Ultibro Breezhaler data

22 February 2018

The chronic obstructive pulmonary disorder (COPD) space is shaping up to become one of pharma’s biggest battle grounds in the next few years as some of the industry’s biggest players compete for dominance.

One of them, Novartis (NOVN: VX), currently has a firm foothold in the market with its Ultibro Breezhaler (indacaterol/glycopyrronium bromide), a treatment developed with UK inhaled therapies developer Vectura Group (LSE: VEC), but executives at the Swiss pharma giant will be aware of the progress being made with triple-combination therapies.

Family-owned Italian drugmaker Chiesi Farmaceutici has presented data showing the superiority of its triple therapy to Ultibro Breezheler and other companies, including the UK-based firms AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: AZN), also have strong evidence supporting their own triple combinations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK